# Bristol-Myers Squibb (BMY) revenue: $48.20B in 2025

URL: https://funkfolio.com/stock/BMY/revenue

> Bristol-Myers Squibb (BMY) revenue was $48.20B in fiscal 2025, down 0.2% from fiscal 2024. Over five fiscal years it grew 2.5% a year.

---

## Bristol-Myers Squibb (BMY) revenue

**Revenue · fiscal 2025:** $48.20B year ended Dec 31, 2025

Bristol-Myers Squibb (BMY) reported revenue of $48.20B in fiscal 2025 (the year ended December 31, 2025). That is 0.2% lower than the $48.30B of fiscal 2024. Figures as of 18 Nov 2026, 10:54 UTC, from the company's filings with the SEC and Yahoo Finance.

### Key facts

- **Revenue, fiscal 2025:** $48.20B
- **Change on fiscal 2024:** −0.2%
- **Growth, 5 years:** +2.5% a year
- **Growth, 10 years:** +11.3% a year
- **Highest on record:** $48.30B fiscal 2024
- **Lowest on record:** $15.62B fiscal 2007
- **Fiscal years on record:** 19 2007–2025

Figures as of 18 Nov 2026, 10:54 UTC. Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

### Bristol-Myers Squibb revenue, in more detail

Over the five fiscal years to 2025 revenue grew at a compound 2.5% a year; over ten years the rate was 11.3% a year. Across the 19 fiscal years on record (2007–2025), the highest was $48.30B in fiscal 2024 and the lowest $15.62B in fiscal 2007.

### Revenue by fiscal year

### Bristol-Myers Squibb revenue, year by year

Bristol-Myers Squibb (BMY) revenue by fiscal year

| Fiscal year | Revenue | Change | Year ended |
| --- | --- | --- | --- |
| 2025 | $48.20B | 0.2% down | Dec 31, 2025 |
| 2024 | $48.30B | 7.3% up | Dec 31, 2024 |
| 2023 | $45.01B | 2.5% down | Dec 31, 2023 |
| 2022 | $46.16B | 0.5% down | Dec 31, 2022 |
| 2021 | $46.39B | 9.1% up | Dec 31, 2021 |
| 2020 | $42.52B | 62.6% up | Dec 31, 2020 |
| 2019 | $26.15B | 15.9% up | Dec 31, 2019 |
| 2018 | $22.56B | 8.6% up | Dec 31, 2018 |
| 2017 | $20.78B | 6.9% up | Dec 31, 2017 |
| 2016 | $19.43B | 17.3% up | Dec 31, 2016 |
| 2015 | $16.56B | 4.3% up | Dec 31, 2015 |
| 2014 | $15.88B | 3.1% down | Dec 31, 2014 |
| 2013 | $16.39B | 7.0% down | Dec 31, 2013 |
| 2012 | $17.62B | 17.1% down | Dec 31, 2012 |
| 2011 | $21.24B | 9.0% up | Dec 31, 2011 |
| 2010 | $19.48B | 3.6% up | Dec 31, 2010 |
| 2009 | $18.81B | 6.2% up | Dec 31, 2009 |
| 2008 | $17.72B | 13.4% up | Dec 31, 2008 |
| 2007 | $15.62B | — | Dec 31, 2007 |

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

### How it is calculated

Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement.

### How to read it

Steady growth in revenue is the raw material for everything else; a fall means the company is selling less or charging less.

### Revenue at health care companies of similar size

Revenue of Bristol-Myers Squibb and comparable companies

| Company | Revenue | Fiscal year |
| --- | --- | --- |
| [Vertex Pharmaceuticals VRTX](https://funkfolio.com/stock/VRTX/revenue) | $12.00B | 2025 |
| [Medtronic MDT](https://funkfolio.com/stock/MDT/revenue) | $36.36B | 2026 |
| Bristol-Myers Squibb BMY | $48.20B | 2025 |
| [Stryker SYK](https://funkfolio.com/stock/SYK/revenue) | $25.12B | 2025 |
| [McKesson MCK](https://funkfolio.com/stock/MCK/revenue) | $403.43B | 2026 |
| [Sanofi SNY](https://funkfolio.com/stock/SNY/revenue) | €46.72B | 2025 |

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

### Bristol-Myers Squibb, figure by figure

- [Bristol-Myers Squibb market cap](https://funkfolio.com/stock/BMY/market-cap)
- [Bristol-Myers Squibb earnings](https://funkfolio.com/stock/BMY/earnings)
- [Bristol-Myers Squibb earnings per share (EPS)](https://funkfolio.com/stock/BMY/eps)
- [Bristol-Myers Squibb P/E ratio](https://funkfolio.com/stock/BMY/pe-ratio)
- [Bristol-Myers Squibb P/S ratio](https://funkfolio.com/stock/BMY/ps-ratio)
- [Bristol-Myers Squibb P/B ratio](https://funkfolio.com/stock/BMY/pb-ratio)
- [Bristol-Myers Squibb free cash flow](https://funkfolio.com/stock/BMY/free-cash-flow)
- [Bristol-Myers Squibb operating margin](https://funkfolio.com/stock/BMY/operating-margin)
- [Bristol-Myers Squibb dividend](https://funkfolio.com/stock/BMY/dividend)
- [Bristol-Myers Squibb shares outstanding](https://funkfolio.com/stock/BMY/shares-outstanding)
- [Bristol-Myers Squibb total debt](https://funkfolio.com/stock/BMY/total-debt)
- [Bristol-Myers Squibb cash on hand](https://funkfolio.com/stock/BMY/cash)
- [Bristol-Myers Squibb total assets](https://funkfolio.com/stock/BMY/total-assets)
- [Bristol-Myers Squibb return on equity (ROE)](https://funkfolio.com/stock/BMY/roe)
- [Bristol-Myers Squibb return on invested capital (ROIC)](https://funkfolio.com/stock/BMY/roic)

[Bristol-Myers Squibb (BMY) overview: price, valuation and scorecard](https://funkfolio.com/stock/BMY) [All health care companies by market value](https://funkfolio.com/companies/sector/health-care)

### Bristol-Myers Squibb revenue: questions and answers

**What is Bristol-Myers Squibb's revenue?**

Bristol-Myers Squibb (BMY) reported revenue of $48.20B in fiscal 2025 (the year ended December 31, 2025). That is 0.2% lower than the $48.30B of fiscal 2024.

**What is the growth rate of Bristol-Myers Squibb's revenue?**

Over the five fiscal years to 2025 revenue grew at a compound 2.5% a year; over ten years the rate was 11.3% a year.

**What are the highest and lowest revenue figures on record for Bristol-Myers Squibb?**

Across the 19 fiscal years on record (2007–2025), the highest was $48.30B in fiscal 2024 and the lowest $15.62B in fiscal 2007.

**How is Bristol-Myers Squibb's revenue calculated?**

Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement. For Bristol-Myers Squibb it is on record here for 19 fiscal years, 2007 to 2025.

Fiscal years are named for the calendar year they end in.

### Learn: revenue

[All stocks guides →](https://funkfolio.com/learn/stocks)

- [Revenue vs earnings vs free cash flow: what each tells you](https://funkfolio.com/learn/stocks/revenue-earnings-free-cash-flow)

  Revenue is everything a company sold in a period. Earnings, or net income, is what remains after every cost, interest and tax. Free cash flow is the cash operations brought in minus spending on long-lived assets. Revenue shows size and demand, earnings show profitability, and free cash flow shows how much cash the business can actually hand out.
- [Altman Z-score: formula, zones and where it fails](https://funkfolio.com/learn/stocks/altman-z-score)

  The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- [Analyst price targets and ratings: what they mean](https://funkfolio.com/learn/stocks/analyst-price-targets)

  An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.

### Cite this page

Funkfolio, “Bristol-Myers Squibb (BMY) revenue”, data as of 18 November 2026. https://funkfolio.com/stock/BMY/revenue

Underlying data: the company's filings with the SEC and Yahoo Finance.
